Sequins™: A New Era in Genomic Control
February 5, 2025, 5:46 am
Location: United States, California, Foster City
Employees: 1-10
Founded date: 2014
In the bustling world of genomics, Sequins™ has emerged as a beacon of innovation. This San Francisco-based start-up is not just another player in the next-generation sequencing (NGS) ecosystem; it’s a game changer. With the launch of its first commercial products, Sequins is poised to redefine how laboratories approach sequencing controls.
Sequins offers two primary products: the Metagenomics Core Control Set and the Whole Genome Sequencing (WGS) Core Control Set. These tools are designed to streamline workflows and enhance the accuracy of genomic analysis. Think of them as the compass and map for researchers navigating the complex landscape of genetic data.
The Sequins Metagenomics Core Control Set is particularly noteworthy. It provides a robust framework for normalizing and quantifying microbial populations in intricate samples. Covering over 50 microbial species, it mirrors the diversity found in real-world environmental samples. This is akin to having a detailed guidebook that not only lists the species but also indicates their relative abundance. Such precision is crucial for researchers aiming to understand microbial ecosystems.
On the other hand, the WGS Core Control Set tackles the intricacies of genetic variants. It encompasses a wide range of variant classes, including challenging genetic variants and structural variants. This set acts like a seasoned navigator, guiding researchers through the often-turbulent waters of genomic data interpretation. By providing a reliable measure of control, Sequins ensures that researchers can trust their results, reducing the risk of errors that could lead to misinterpretations.
The technology behind Sequins is rooted in synthetic nucleic acids that replicate naturally occurring sequences. This innovative approach allows for accurate representation of genomic complexity without compromising sample integrity. Imagine a mirror that reflects not just the surface but the depth of the image. Sequins does just that for genomic data, ensuring that researchers have a true representation of their samples.
In addition to these core products, Sequins is also launching an evaluation program for circulating tumor DNA (ctDNA) controls. This program is a significant step forward in cancer research, providing a customizable backbone for monitoring workflows and calibrating detection limits. It covers nine critical cancer genes, offering researchers a powerful tool to enhance their assays. This is akin to having a tailored suit; it fits perfectly to the unique needs of each research project.
The leadership at Sequins is equally impressive. The company recently welcomed Jeremy Preston as Senior Vice President. With over 20 years of experience in the genomics field, Preston brings a wealth of knowledge and expertise. His previous roles at industry giants like Affymetrix and Illumina position him as a key player in driving Sequins’ growth. His vision aligns with the company’s mission to become a foundational component of NGS assays. It’s like adding a seasoned captain to a ship, steering it toward uncharted waters with confidence.
Sequins is not just about products; it’s about creating a universal platform for internal standards. This ambition reflects a commitment to quality and innovation. The company has invested heavily in production and quality control capabilities, ensuring that its products meet the highest standards. This dedication is crucial in an industry where precision is paramount.
As Sequins rolls out its products, it is also building a robust infrastructure to support customer adoption. The goal is to foster rapid growth while maintaining a focus on quality. This dual approach is essential in a competitive landscape where speed and accuracy are often at odds. By prioritizing both, Sequins is setting itself apart from the competition.
The implications of Sequins’ technology extend beyond individual laboratories. As the genomics industry evolves, the need for standardized controls becomes increasingly critical. Sequins is stepping into this gap, offering solutions that enhance assay development and improve overall testing accuracy. This is akin to laying down a solid foundation for a skyscraper; without it, the structure is at risk of collapse.
Moreover, Sequins’ products have the potential to influence best practices across the genomics landscape. By providing reliable controls, the company is empowering researchers to adopt more rigorous methodologies. This shift could lead to breakthroughs in various fields, from environmental science to personalized medicine.
In conclusion, Sequins™ is not just introducing products; it’s ushering in a new era of genomic control. With its innovative technology, experienced leadership, and commitment to quality, Sequins is well-positioned to become a cornerstone of the NGS ecosystem. As researchers embrace these tools, the potential for discovery is limitless. The future of genomics is bright, and Sequins is leading the charge.
Sequins offers two primary products: the Metagenomics Core Control Set and the Whole Genome Sequencing (WGS) Core Control Set. These tools are designed to streamline workflows and enhance the accuracy of genomic analysis. Think of them as the compass and map for researchers navigating the complex landscape of genetic data.
The Sequins Metagenomics Core Control Set is particularly noteworthy. It provides a robust framework for normalizing and quantifying microbial populations in intricate samples. Covering over 50 microbial species, it mirrors the diversity found in real-world environmental samples. This is akin to having a detailed guidebook that not only lists the species but also indicates their relative abundance. Such precision is crucial for researchers aiming to understand microbial ecosystems.
On the other hand, the WGS Core Control Set tackles the intricacies of genetic variants. It encompasses a wide range of variant classes, including challenging genetic variants and structural variants. This set acts like a seasoned navigator, guiding researchers through the often-turbulent waters of genomic data interpretation. By providing a reliable measure of control, Sequins ensures that researchers can trust their results, reducing the risk of errors that could lead to misinterpretations.
The technology behind Sequins is rooted in synthetic nucleic acids that replicate naturally occurring sequences. This innovative approach allows for accurate representation of genomic complexity without compromising sample integrity. Imagine a mirror that reflects not just the surface but the depth of the image. Sequins does just that for genomic data, ensuring that researchers have a true representation of their samples.
In addition to these core products, Sequins is also launching an evaluation program for circulating tumor DNA (ctDNA) controls. This program is a significant step forward in cancer research, providing a customizable backbone for monitoring workflows and calibrating detection limits. It covers nine critical cancer genes, offering researchers a powerful tool to enhance their assays. This is akin to having a tailored suit; it fits perfectly to the unique needs of each research project.
The leadership at Sequins is equally impressive. The company recently welcomed Jeremy Preston as Senior Vice President. With over 20 years of experience in the genomics field, Preston brings a wealth of knowledge and expertise. His previous roles at industry giants like Affymetrix and Illumina position him as a key player in driving Sequins’ growth. His vision aligns with the company’s mission to become a foundational component of NGS assays. It’s like adding a seasoned captain to a ship, steering it toward uncharted waters with confidence.
Sequins is not just about products; it’s about creating a universal platform for internal standards. This ambition reflects a commitment to quality and innovation. The company has invested heavily in production and quality control capabilities, ensuring that its products meet the highest standards. This dedication is crucial in an industry where precision is paramount.
As Sequins rolls out its products, it is also building a robust infrastructure to support customer adoption. The goal is to foster rapid growth while maintaining a focus on quality. This dual approach is essential in a competitive landscape where speed and accuracy are often at odds. By prioritizing both, Sequins is setting itself apart from the competition.
The implications of Sequins’ technology extend beyond individual laboratories. As the genomics industry evolves, the need for standardized controls becomes increasingly critical. Sequins is stepping into this gap, offering solutions that enhance assay development and improve overall testing accuracy. This is akin to laying down a solid foundation for a skyscraper; without it, the structure is at risk of collapse.
Moreover, Sequins’ products have the potential to influence best practices across the genomics landscape. By providing reliable controls, the company is empowering researchers to adopt more rigorous methodologies. This shift could lead to breakthroughs in various fields, from environmental science to personalized medicine.
In conclusion, Sequins™ is not just introducing products; it’s ushering in a new era of genomic control. With its innovative technology, experienced leadership, and commitment to quality, Sequins is well-positioned to become a cornerstone of the NGS ecosystem. As researchers embrace these tools, the potential for discovery is limitless. The future of genomics is bright, and Sequins is leading the charge.